Pulmonary Arterial Hypertension - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H1 2019’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension

- The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects

- The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aadi Bioscience Inc

Acceleron Pharma Inc

Actelion Pharmaceuticals Ltd

Aerogen Ltd

AI Therapeutics

AVEO Pharmaceuticals Inc

Bayer AG

Bial - Portela & Ca SA

Biogen ...

Aadi Bioscience Inc

Acceleron Pharma Inc

Actelion Pharmaceuticals Ltd

Aerogen Ltd

AI Therapeutics

AVEO Pharmaceuticals Inc

Bayer AG

Bial - Portela & Ca SA

Biogen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chugai Pharmaceutical Co Ltd

Complexa Inc

Denovo Biopharma LLC

Eli Lilly and Co

Gilead Sciences Inc

GlaxoSmithKline Plc

Gossamer Bio Inc

Insmed Inc

Insys Therapeutics Inc

Japan Tobacco Inc

Liquidia Technologies Inc

Martin Pharmaceuticals Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Nippon Shinyaku Co Ltd

Nissan Chemical Corp

Northern Therapeutics Inc

Novartis AG

Peloton Therapeutics Inc

PhaseBio Pharmaceuticals Inc

Pulmokine Inc

Q BioMed Inc

Radikal Therapeutics Inc

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Respira Therapeutics Inc

Resverlogix Corp

Reviva Pharmaceuticals Inc

SteadyMed Therapeutics Inc

Suda Pharmaceuticals Ltd

Takeda Pharmaceutical Co Ltd

Toray Industries Inc

United Therapeutics Corp

Vicore Pharma AB

Vivus Inc

Table of Contents

Table of Contents

Introduction

Pulmonary Arterial Hypertension – Overview

Pulmonary Arterial Hypertension – Therapeutics Development

Pulmonary Arterial Hypertension – Therapeutics Assessment

Pulmonary Arterial Hypertension – ...

Table of Contents

Introduction

Pulmonary Arterial Hypertension – Overview

Pulmonary Arterial Hypertension – Therapeutics Development

Pulmonary Arterial Hypertension – Therapeutics Assessment

Pulmonary Arterial Hypertension – Companies Involved in Therapeutics Development

Pulmonary Arterial Hypertension – Drug Profiles

Pulmonary Arterial Hypertension – Dormant Projects

Pulmonary Arterial Hypertension – Discontinued Products

Pulmonary Arterial Hypertension – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Aadi Bioscience Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Acceleron Pharma Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Actelion Pharmaceuticals Ltd, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Aerogen Ltd, H1 2019

Pulmonary Arterial Hypertension – Pipeline by AI Therapeutics, H1 2019

Pulmonary Arterial Hypertension – Pipeline by AVEO Pharmaceuticals Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Bayer AG, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Bial - Portela & Ca SA, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Biogen Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Boehringer Ingelheim GmbH, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Bristol-Myers Squibb Co, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Camurus AB, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Capricor Therapeutics Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Celsion Corp, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Celtaxsys Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Chiesi Farmaceutici SpA, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Complexa Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Denovo Biopharma LLC, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Eli Lilly and Co, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Gilead Sciences Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by GlaxoSmithKline Plc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Gossamer Bio Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Insmed Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Insys Therapeutics Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Japan Tobacco Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Liquidia Technologies Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Martin Pharmaceuticals Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Merck & Co Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Mezzion Pharma Co Ltd, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Nippon Shinyaku Co Ltd, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Nissan Chemical Corp, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Northern Therapeutics Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Novartis AG, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Peloton Therapeutics Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by PhaseBio Pharmaceuticals Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Pulmokine Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Q BioMed Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Radikal Therapeutics Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Reata Pharmaceuticals Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Relief Therapeutics Holding AG, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Respira Therapeutics Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Resverlogix Corp, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Reviva Pharmaceuticals Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by SteadyMed Therapeutics Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Suda Pharmaceuticals Ltd, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Toray Industries Inc, H1 2019

Pulmonary Arterial Hypertension – Pipeline by United Therapeutics Corp, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Vicore Pharma AB, H1 2019

Pulmonary Arterial Hypertension – Pipeline by Vivus Inc, H1 2019

Pulmonary Arterial Hypertension – Dormant Projects, H1 2019

Pulmonary Arterial Hypertension – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports